94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Cell Death
Sec. Model Systems in Cell Death
Volume 4 - 2025 | doi: 10.3389/fceld.2025.1499694
Prediction of Prognosis and Treatment Effect of Cervical Cancer by Immunogenic Cell Death-related Genes
Provisionally accepted- 1 Qingdao University, Qingdao, Shandong Province, China
- 2 The Affiliated Hospital of Qingdao University, Qingdao, China
Background: Immunogenic cell death (ICD) is a potential mechanism that mediates adaptive immune responses during anticancer therapy. However, the characteristics of ICDs in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) remain unclear. This study aimed to investigate the association of ICD-related genes with immune characteristics, prognosis, and immune checkpoint blocking (ICB) efficacy in CESC and to predict the response to drugs in different risk groups. Methods: We obtained the RNA-seq transcriptome information, standard normalized variate (SNV) data, and matched clinicopathological data from The Cancer Genome Atlas (TCGA). Two ICDrelated subtypes were identified by consensus clustering. Minimum absolute contraction and selection operator (LASSO) regression was used to construct the prognosis prediction models. The model was verified using immunohistochemistry and ROC curve analyses. The effect of immunotherapy was predicted based on model scores. Results: ICD-high subtype (C2) was associated with favorable clinical outcomes and highly active immune response signals. The constructed prediction model genes included ATG5, FOXP3, IFNG, IL1B, PDIA3, and TNF. Immunohistochemical confirmed that the expression of ATG5 and PDIA3 was higher in cervical cancer tissues than in normal cervical tissues, and the ROC curve confirmed the validity of the model. In addition, immunophenoscore (IPS) and tumor immune dysfunction and elimination (TIDE) scores indicated that patients in the low-risk group fared better on PD1 therapy and immunotherapy. Conclusions: We analyzed the differential expression of ICD-related genes, established and verified a new ICD-signaturebased CESC classification system, and performed immunomicroenvironmental correlation analysis based on this classification to evaluate the prognosis and clinical efficacy of immunotherapy in patients with CECS. This could help screen candidates for cervical cancer that may benefit from immunotherapy.
Keywords: Uterine Cervical Neoplasms, Immunogenic cell death, prognosis, Immunotherapy, Model
Received: 21 Sep 2024; Accepted: 27 Feb 2025.
Copyright: © 2025 Li, Wang, Sun, Huang, Kong and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Tian Tian, The Affiliated Hospital of Qingdao University, Qingdao, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.